Brucato, Antonio
Imazio, Massimo
Cremer, Paul C.
Adler, Yehuda
Maisch, Bernhard
Lazaros, George
Gattorno, Marco
Caforio, Alida L. P.
Marcolongo, Renzo
Emmi, Giacomo http://orcid.org/0000-0001-9575-8321
Martini, Alberto
Klein, Allan L.
Article History
Received: 1 May 2018
Accepted: 10 July 2018
First Online: 18 July 2018
Compliance with ethical standards
:
: Antonio Luca Brucato has received research grants from Acarpia, Sobi, and Lilly, and speaker fees from Sobi, Menarini, and Novartis; Massimo Imazio has received an institutional research grant from Acarpia e SOBI. Paul C. Cremer, Yehuda Adler, Bernhard Maisch, and George Lazaros and Alida L.P. Caforio declare that they have no conflict of interest; Alberto Martini has no conflict of interest to declare, since starting from 1 March 2016 he has become the Scientific Director of the G. Gaslini Hospital; therefore, his role does not allow rendering private consultancies resulting in personal income. He has performed consultancy activities on behalf of the Gaslini Institute for the companies listed below. Abbvie, Biogen, Boehringer, Bristol Myers and Squibb, EMD Serono, Janssen, Novartis, Pfizer, and R-Pharm. The money received for these activities are directly transferred to the Gaslini Institute’s bank account; Marco Gattorno has received research grants and speaker fees from Novartis and Sobi; Renzo Marcolongo has received fee for consultancy from SOBI; Giacomo Emmi has received fees for consultancy from SOBI, GSK, and Novartis; Allan L. Klein has received research grant from Kiniksa. The authors declare that they have no conflict of interest.
: This article does not contain any studies with human participants or animals performed by any of the authors.
: For this type of study, formal consent is not required.